Progress on COVID-19 Chemotherapeutics Discovery and Novel Technology

COVID-19 is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel highly contagious and pathogenic coronavirus that emerged in late 2019. SARS-CoV-2 spreads primarily through virus-containing droplets and small particles of air pollution, which greatly...

Full description

Saved in:
Bibliographic Details
Published inMolecules (Basel, Switzerland) Vol. 27; no. 23; p. 8257
Main Authors Zhou, Yalan, Wang, Huizhen, Yang, Li, Wang, Qingzhong
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 26.11.2022
MDPI
Subjects
Antiviral agents
Antiviral Agents - chemistry
Antiviral Agents - pharmacology
Antiviral Agents - therapeutic use
Antiviral drugs
Bioavailability
Biosynthesis
Chemotherapy
China
Clinical trials
Coronaviruses
COVID-19
COVID-19 vaccines
CRISPR/Cas
Cytokine storm
deep learning
Disease prevention
Disease transmission
Drug development
drug target
Drug therapy
Enzymes
Epidemics
Experiments
Genomes
Humans
Interferon
multiomics analysis
Pandemics
Proteins
Review
SARS-CoV-2
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Technology
Vaccines
Viral infections
Viruses
China
COVID-19
deep learning
SARS-CoV-2
multiomics analysis
CRISPR/Cas
drug target
Online AccessGet full text

Cover

Abstract COVID-19 is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel highly contagious and pathogenic coronavirus that emerged in late 2019. SARS-CoV-2 spreads primarily through virus-containing droplets and small particles of air pollution, which greatly increases the risk of inhaling these virus particles when people are in close proximity. COVID-19 is spreading across the world, and the COVID-19 pandemic poses a threat to human health and public safety. To date, there are no specific vaccines or effective drugs against SARS-CoV-2. In this review, we focus on the enzyme targets of the virus and host that may be critical for the discovery of chemical compounds and natural products as antiviral drugs, and describe the development of potential antiviral drugs in the preclinical and clinical stages. At the same time, we summarize novel emerging technologies applied to the research on new drug development and the pathological mechanisms of COVID-19.
AbstractList COVID-19 is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel highly contagious and pathogenic coronavirus that emerged in late 2019. SARS-CoV-2 spreads primarily through virus-containing droplets and small particles of air pollution, which greatly increases the risk of inhaling these virus particles when people are in close proximity. COVID-19 is spreading across the world, and the COVID-19 pandemic poses a threat to human health and public safety. To date, there are no specific vaccines or effective drugs against SARS-CoV-2. In this review, we focus on the enzyme targets of the virus and host that may be critical for the discovery of chemical compounds and natural products as antiviral drugs, and describe the development of potential antiviral drugs in the preclinical and clinical stages. At the same time, we summarize novel emerging technologies applied to the research on new drug development and the pathological mechanisms of COVID-19.
COVID-19 is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel highly contagious and pathogenic coronavirus that emerged in late 2019. SARS-CoV-2 spreads primarily through virus-containing droplets and small particles of air pollution, which greatly increases the risk of inhaling these virus particles when people are in close proximity. COVID-19 is spreading across the world, and the COVID-19 pandemic poses a threat to human health and public safety. To date, there are no specific vaccines or effective drugs against SARS-CoV-2. In this review, we focus on the enzyme targets of the virus and host that may be critical for the discovery of chemical compounds and natural products as antiviral drugs, and describe the development of potential antiviral drugs in the preclinical and clinical stages. At the same time, we summarize novel emerging technologies applied to the research on new drug development and the pathological mechanisms of COVID-19.COVID-19 is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel highly contagious and pathogenic coronavirus that emerged in late 2019. SARS-CoV-2 spreads primarily through virus-containing droplets and small particles of air pollution, which greatly increases the risk of inhaling these virus particles when people are in close proximity. COVID-19 is spreading across the world, and the COVID-19 pandemic poses a threat to human health and public safety. To date, there are no specific vaccines or effective drugs against SARS-CoV-2. In this review, we focus on the enzyme targets of the virus and host that may be critical for the discovery of chemical compounds and natural products as antiviral drugs, and describe the development of potential antiviral drugs in the preclinical and clinical stages. At the same time, we summarize novel emerging technologies applied to the research on new drug development and the pathological mechanisms of COVID-19.
Audience Academic
Author Yang, Li
Zhou, Yalan
Wang, Qingzhong
Wang, Huizhen
AuthorAffiliation Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
AuthorAffiliation_xml – name: Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
Author_xml – sequence: 1
  givenname: Yalan
  surname: Zhou
  fullname: Zhou, Yalan
– sequence: 2
  givenname: Huizhen
  surname: Wang
  fullname: Wang, Huizhen
– sequence: 3
  givenname: Li
  surname: Yang
  fullname: Yang, Li
– sequence: 4
  givenname: Qingzhong
  orcidid: 0000-0001-7472-996X
  surname: Wang
  fullname: Wang, Qingzhong
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36500347$$D View this record in MEDLINE/PubMed
BookMark eNp9kk1v1DAQhi1URD_gB3BBkbhwSfFnHF-Qqm2BlSrKoXC1HGeS9SqxFzuptP8eL1tKtyDkg0fjZ97XM5pTdOSDB4ReE3zOmMLvxzCAnQdIVFJWUyGfoRPCKS4Z5uroUXyMTlNaY0wJJ-IFOmaVwJhxeYKuvsbQR0ipCL5Y3HxfXpZEFYsVjGFaQTQbmCdnU3Hpkg13ELeF8W3xJYdDcQt25cMQ-u1L9LwzQ4JX9_cZ-vbx6nbxuby--bRcXFyXVlR4KgWrcXauwZJWNJx0nSK4wp2UjHLKVAOYMiwsSNGoSjXMCsJbSkknaVs1NTtDy71uG8xab6IbTdzqYJz-lQix1ybm_w6gbfYwVFErK8zrRjSWWc6kwoqq7MSz1oe91mZuRmgt-Cma4UD08MW7le7DnVaSVRVnWeDdvUAMP2ZIkx7zkGAYjIcwJ02lYIzUgpKMvn2CrsMcfR5Vpnidh0Nk9YfqTW7A-S5kX7sT1ReSC1VxqXbU-T-ofFoYnc0L0rmcPyh487jRhw5_L0EGyB6wMaQUoXtACNa7RdN_LVqukU9qrJvM5MJuVm74T-VPyi_Wtw
CitedBy_id crossref_primary_10_1016_j_str_2024_10_025
crossref_primary_10_1016_j_heliyon_2024_e24209
crossref_primary_10_1111_febs_16947
crossref_primary_10_3390_molecules28031080
crossref_primary_10_3390_cimb45010028
Cites_doi 10.1016/j.joim.2020.02.005
10.3389/fimmu.2021.590742
10.1016/j.cell.2021.03.055
10.1126/science.abh2644
10.1073/pnas.1323705111
10.1016/S1470-2045(05)70101-7
10.1038/s41580-021-00418-x
10.1177/0194599820981018
10.1038/s41586-020-2223-y
10.1038/s41591-021-01329-2
10.1002/lary.29286
10.1016/S0140-6736(20)31022-9
10.1126/science.1085658
10.1016/S0140-6736(20)30211-7
10.1038/s41586-020-2575-3
10.1038/s41586-020-2286-9
10.1038/s41423-020-00619-y
10.1002/jmv.27188
10.1016/j.cels.2020.10.003
10.1016/j.jmii.2020.05.001
10.4103/ijp.IJP_115_20
10.1016/j.bpj.2021.06.016
10.1186/s13020-021-00542-y
10.1038/s41467-021-25729-7
10.7554/eLife.66815
10.1128/AAC.01156-16
10.1016/j.bbrc.2022.07.087
10.1128/jvi.00671-22
10.1001/jamanetworkopen.2021.3071
10.2807/1560-7917.ES.2021.26.16.2100348
10.1002/cpt.2603
10.1016/j.molstruc.2022.132602
10.1016/j.ejphar.2020.173836
10.1038/s41592-021-01124-4
10.1016/j.it.2020.10.004
10.1007/s43440-020-00195-y
10.1016/j.cell.2020.10.037
10.1016/j.biopha.2022.113058
10.1038/s41586-020-2332-7
10.1016/j.molcel.2016.12.023
10.1126/science.abl4784
10.1073/pnas.2117142119
10.1016/j.virs.2022.01.008
10.1016/j.jmgm.2021.107904
10.1038/s41467-022-28354-0
10.1038/s41586-021-03402-9
10.1124/dmd.121.000801
10.1016/j.imu.2021.100516
10.1038/s41401-020-0483-6
10.1099/jgv.0.001558
10.1016/j.mib.2017.05.008
10.3389/fendo.2021.671946
10.1038/s41586-021-03412-7
10.1038/s41467-020-18709-w
10.1016/j.csbj.2021.08.036
10.1038/s41579-020-00461-z
10.1073/pnas.2025581118
10.3389/fcimb.2020.587269
10.1002/ptr.7294
10.1016/j.antiviral.2020.104996
10.1128/AAC.02428-20
10.1016/j.ygeno.2020.11.009
10.1016/j.molstruc.2020.129026
10.1021/acs.jproteome.0c00316
10.1016/j.mehy.2020.110394
10.1016/j.jbc.2021.100770
10.1016/j.drup.2021.100794
10.1039/D1RA03956C
10.1016/j.cell.2020.04.020
10.1016/S2666-7568(21)00168-9
10.1016/j.virol.2008.08.026
10.1021/acsomega.0c03682
10.1038/s41392-021-00809-8
10.1016/j.ijantimicag.2020.105948
10.1038/s41467-022-28113-1
10.1002/anbr.202000024
10.1002/minf.202000028
10.1128/JVI.00998-13
10.1093/cid/ciaa1866
10.1021/acs.jmedchem.0c00606
10.1038/s41586-020-2012-7
10.3390/v4061011
10.2202/1544-6115.1470
10.7554/eLife.64508
10.1016/S0140-6736(21)02657-X
10.1016/j.apsb.2020.10.002
10.1038/s41422-020-0282-0
10.1056/NEJMp2032369
10.1016/j.compbiomed.2021.104359
10.3390/biomedicines9060689
10.1038/s41564-020-00835-2
10.1016/j.molcel.2021.01.035
10.1038/d41573-020-00016-0
10.1016/j.compbiolchem.2022.107764
10.1038/nrmicro2090
10.1080/14756366.2021.1954919
10.1093/bib/bbab211
10.3390/ijms22179124
10.1128/JVI.02346-12
10.1016/j.celrep.2021.109892
10.1186/s12879-020-05698-w
10.1093/bib/bbac226
10.1016/j.jcv.2021.105019
10.1126/science.abg3055
10.1070/RCR4791
10.12659/MSM.935952
10.3390/molecules26226900
10.1038/nrd.2015.37
10.1007/s10096-020-04138-6
10.1016/S0140-6736(21)01358-1
10.1016/j.cell.2018.09.001
10.1080/07391102.2019.1702588
10.1016/j.ejps.2018.10.020
10.1002/ange.202008835
10.1038/s41467-020-18096-2
10.1016/j.chest.2021.01.087
10.2217/fmb-2021-0252
10.1038/s41594-020-00549-3
10.1186/s13063-021-05538-5
10.1016/j.cell.2021.05.033
10.1126/science.abc1560
10.1038/s41586-021-03426-1
10.1201/9781003039235-23
10.1016/j.jddst.2021.102634
10.1016/j.cct.2020.106239
10.1186/s13578-021-00643-z
10.7150/ijms.53685
10.1016/S0140-6736(20)30183-5
10.1016/j.csbj.2020.03.025
10.1007/s11427-020-1637-5
10.1051/e3sconf/202127302025
10.1080/22221751.2020.1719902
10.1073/pnas.2111199119
10.1016/j.apsb.2021.06.016
10.1016/S2666-5247(21)00068-9
10.1126/scitranslmed.abb5883
10.1016/j.micpath.2020.104641
ContentType Journal Article
Copyright COPYRIGHT 2022 MDPI AG
2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2022 by the authors. 2022
Copyright_xml – notice: COPYRIGHT 2022 MDPI AG
– notice: 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2022 by the authors. 2022
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
COVID
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.3390/molecules27238257
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
Coronavirus Research Database
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni)
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
Coronavirus Research Database
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList CrossRef


MEDLINE - Academic

MEDLINE
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Chemistry
EISSN 1420-3049
ExternalDocumentID oai_doaj_org_article_cc1da292c76048b5bc3c4379092939b4
PMC9736643
A745964796
36500347
10_3390_molecules27238257
Genre Journal Article
Review
GeographicLocations China
GeographicLocations_xml – name: China
GrantInformation_xml – fundername: Shanghai University of Traditional Chinese Medicine
  grantid: 2020XGKY12
– fundername: National Natural Science Foundation of China
  grantid: 31871281
– fundername: Scientific Research Foundation for Advanced Talents of Shanghai University of Traditional Chinese Medicine, the Shanghai Municipal Health Commission
  grantid: 2020XGKY12
GroupedDBID ---
0R~
123
2WC
53G
5VS
7X7
88E
8FE
8FG
8FH
8FI
8FJ
A8Z
AADQD
AAFWJ
AAHBH
AAYXX
ABDBF
ABUWG
ACGFO
ACIWK
ACPRK
ACUHS
AEGXH
AENEX
AFKRA
AFPKN
AFRAH
AFZYC
AIAGR
ALIPV
ALMA_UNASSIGNED_HOLDINGS
BENPR
BPHCQ
BVXVI
CCPQU
CITATION
CS3
D1I
DIK
DU5
E3Z
EBD
EMOBN
ESX
FYUFA
GROUPED_DOAJ
GX1
HH5
HMCUK
HYE
HZ~
I09
IAO
IHR
ITC
KQ8
LK8
M1P
MODMG
O-U
O9-
OK1
P2P
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RPM
SV3
TR2
TUS
UKHRP
~8M
3V.
ABJCF
BBNVY
BHPHI
CGR
CUY
CVF
ECM
EIF
HCIFZ
KB.
M7P
M~E
NPM
PDBOC
PMFND
7XB
8FK
AZQEC
COVID
DWQXO
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c560t-53806508ec1d5b41ff91060f77324239be02305ce75b969b3c514d221f72d6b83
IEDL.DBID 7X7
ISSN 1420-3049
IngestDate Wed Aug 27 01:28:37 EDT 2025
Thu Aug 21 18:39:02 EDT 2025
Fri Jul 11 08:49:02 EDT 2025
Fri Jul 25 09:33:16 EDT 2025
Thu May 08 04:13:31 EDT 2025
Tue Jun 10 20:53:16 EDT 2025
Wed Feb 19 02:26:20 EST 2025
Tue Jul 01 01:21:38 EDT 2025
Thu Apr 24 23:11:29 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 23
Keywords COVID-19
deep learning
SARS-CoV-2
multiomics analysis
CRISPR/Cas
drug target
Language English
License https://creativecommons.org/licenses/by/4.0
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c560t-53806508ec1d5b41ff91060f77324239be02305ce75b969b3c514d221f72d6b83
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0001-7472-996X
OpenAccessLink https://www.proquest.com/docview/2748560176?pq-origsite=%requestingapplication%
PMID 36500347
PQID 2748560176
PQPubID 2032355
ParticipantIDs doaj_primary_oai_doaj_org_article_cc1da292c76048b5bc3c4379092939b4
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9736643
proquest_miscellaneous_2753318521
proquest_journals_2748560176
gale_infotracmisc_A745964796
gale_infotracacademiconefile_A745964796
pubmed_primary_36500347
crossref_primary_10_3390_molecules27238257
crossref_citationtrail_10_3390_molecules27238257
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20221126
PublicationDateYYYYMMDD 2022-11-26
PublicationDate_xml – month: 11
  year: 2022
  text: 20221126
  day: 26
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle Molecules (Basel, Switzerland)
PublicationTitleAlternate Molecules
PublicationYear 2022
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Vandenberg (ref_6) 2021; 19
Faria (ref_105) 2021; 372
Mykytyn (ref_22) 2021; 10
Lamers (ref_23) 2021; 10
Garibaldi (ref_91) 2021; 4
Hassaniazad (ref_148) 2021; 35
Zhang (ref_134) 2018; 175
Glende (ref_97) 2008; 381
Zhuo (ref_112) 2021; 379
Dejnirattisai (ref_106) 2021; 184
Saniasiaya (ref_4) 2021; 165
Xu (ref_137) 2021; 18
Beyerstedt (ref_15) 2021; 40
Su (ref_144) 2020; 183
Abbott (ref_136) 2020; 181
Wondmkun (ref_28) 2020; 14
Saniasiaya (ref_3) 2021; 131
Zhu (ref_2) 2020; 38
Baranovich (ref_83) 2013; 87
Gao (ref_7) 2021; 54
Zhang (ref_131) 2020; 18
Collier (ref_109) 2021; 593
Razizadeh (ref_117) 2021; 120
Wang (ref_127) 2021; 22
Chen (ref_146) 2021; 11
Xiang (ref_31) 2022; 12
Jin (ref_37) 2020; 582
Subissi (ref_54) 2014; 111
Rohaim (ref_38) 2021; 150
Khiali (ref_80) 2022; 17
Zhao (ref_52) 2019; 127
Funk (ref_102) 2021; 26
Adedeji (ref_116) 2013; 87
Zhang (ref_39) 2022; 23
Rubin (ref_90) 2020; 383
Heskin (ref_46) 2022; 399
Singh (ref_48) 2022; 112
Sahin (ref_66) 2021; 93
Belouzard (ref_95) 2012; 4
Wang (ref_11) 2021; 12
Koonin (ref_132) 2017; 37
Owen (ref_43) 2021; 374
Huang (ref_5) 2020; 395
Roe (ref_34) 2021; 102
Xiang (ref_62) 2021; 16
Peng (ref_85) 2021; 2
Smargon (ref_133) 2017; 65
ref_147
Gan (ref_12) 2021; 185
Wang (ref_65) 2021; 18
Sheahan (ref_75) 2020; 12
Tegally (ref_104) 2021; 592
Davies (ref_101) 2021; 593
Brant (ref_88) 2021; 11
Xu (ref_13) 2020; 63
Tut (ref_108) 2021; 2
Wang (ref_18) 2020; 10
ref_86
Gil (ref_27) 2020; 63
Yu (ref_99) 2022; 119
Parums (ref_73) 2022; 28
Yan (ref_78) 2021; 184
Bai (ref_26) 2021; 146
Bojkova (ref_139) 2020; 583
Das (ref_123) 2021; 113
Ghosh (ref_125) 2021; 1224
Jangra (ref_103) 2021; 2
Padhi (ref_113) 2021; 894
Dillman (ref_56) 2021; 101
Vanderlinden (ref_84) 2016; 60
Naidu (ref_68) 2021; 18
Yin (ref_92) 2020; 368
Keller (ref_57) 2021; 160
Bravo (ref_93) 2021; 81
Pourfarjam (ref_69) 2022; 625
Boonma (ref_114) 2022; 101
ref_51
Zielinski (ref_138) 2021; 12
Zumla (ref_29) 2016; 15
Silva (ref_41) 2021; 11
Cohen (ref_10) 2020; 73
Eng (ref_47) 2022; 50
Villa (ref_82) 2005; 6
Rosik (ref_130) 2021; 59
Ibrahim (ref_64) 2021; 105
Khan (ref_135) 2021; 145
Ching (ref_59) 2021; 64
Chan (ref_14) 2020; 9
ref_60
Sheikh (ref_107) 2021; 397
Campagnola (ref_71) 2022; 96
Harrison (ref_20) 2020; 41
Painter (ref_77) 2021; 65
Stephenson (ref_140) 2021; 27
Beck (ref_128) 2020; 18
ref_63
Su (ref_61) 2020; 41
Cox (ref_76) 2021; 6
Jonsdottir (ref_79) 2022; 150
Zhou (ref_118) 2022; 94
Su (ref_49) 2021; 133
Davies (ref_100) 2021; 372
Jackson (ref_19) 2022; 23
Dohrn (ref_53) 2021; 3
Zeng (ref_122) 2020; 19
Overmyer (ref_141) 2021; 12
ref_115
Ivanov (ref_121) 2020; 5
ref_119
Xin (ref_16) 2021; 1
Zhao (ref_33) 2022; 119
Yan (ref_35) 2021; 19
Sarma (ref_67) 2022; 1257
Kaur (ref_120) 2021; 73
Gordon (ref_143) 2020; 583
Wang (ref_1) 2020; 55
Chen (ref_25) 2020; 395
Shannon (ref_70) 2022; 13
Wang (ref_89) 2020; 30
Anand (ref_36) 2003; 300
Abdelnabi (ref_45) 2022; 13
Douangamath (ref_50) 2020; 11
Witten (ref_142) 2009; 8
Du (ref_96) 2009; 7
Beumer (ref_21) 2021; 12
Prajapat (ref_72) 2020; 52
Ton (ref_126) 2020; 39
Zhang (ref_145) 2021; 18
Aghaee (ref_40) 2021; 23
Gordon (ref_81) 2021; 297
Zitnik (ref_124) 2021; 118
Li (ref_30) 2020; 19
Pablos (ref_32) 2021; 37
ref_44
Vuong (ref_58) 2020; 11
Xiao (ref_98) 2021; 28
Kadioglu (ref_129) 2021; 133
Zou (ref_55) 2022; 37
Wang (ref_94) 2020; 395
Pavan (ref_42) 2021; 36
Zhou (ref_110) 2020; 579
Balakin (ref_111) 2018; 87
ref_9
ref_8
Holman (ref_74) 2021; 22
Gong (ref_17) 2021; 6
Hoffmann (ref_24) 2020; 585
Ayipo (ref_87) 2022; 40
References_xml – volume: 18
  start-page: 152
  year: 2020
  ident: ref_131
  article-title: In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus
  publication-title: J. Integr. Med.
  doi: 10.1016/j.joim.2020.02.005
– volume: 40
  start-page: 1
  year: 2022
  ident: ref_87
  article-title: Molecular modelling and structure-activity relationship of a natural derivative of o-hydroxybenzoate as a potent inhibitor of dual NSP3 and NSP12 of SARS-CoV-2: In silico study
  publication-title: J. Biomol. Struct. Dyn.
– ident: ref_9
– volume: 12
  start-page: 590742
  year: 2021
  ident: ref_138
  article-title: High Throughput Multi-Omics Approaches for Clinical Trial Evaluation and Drug Discovery
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2021.590742
– volume: 184
  start-page: 2939
  year: 2021
  ident: ref_106
  article-title: Antibody evasion by the P.1 strain of SARS-CoV-2
  publication-title: Cell
  doi: 10.1016/j.cell.2021.03.055
– volume: 372
  start-page: 815
  year: 2021
  ident: ref_105
  article-title: Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil
  publication-title: Science
  doi: 10.1126/science.abh2644
– volume: 111
  start-page: E3900
  year: 2014
  ident: ref_54
  article-title: One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.1323705111
– volume: 6
  start-page: 271
  year: 2005
  ident: ref_82
  article-title: Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(05)70101-7
– volume: 23
  start-page: 3
  year: 2022
  ident: ref_19
  article-title: Mechanisms of SARS-CoV-2 entry into cells
  publication-title: Nat. Rev. Mol. Cell Biol.
  doi: 10.1038/s41580-021-00418-x
– volume: 165
  start-page: 33
  year: 2021
  ident: ref_4
  article-title: Prevalence and Characteristics of Taste Disorders in Cases of COVID-19: A Meta-analysis of 29,349 Patients
  publication-title: Otolaryngol. Head Neck Surg.
  doi: 10.1177/0194599820981018
– volume: 582
  start-page: 289
  year: 2020
  ident: ref_37
  article-title: Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors
  publication-title: Nature
  doi: 10.1038/s41586-020-2223-y
– volume: 27
  start-page: 904
  year: 2021
  ident: ref_140
  article-title: Single-cell multi-omics analysis of the immune response in COVID-19
  publication-title: Nat. Med.
  doi: 10.1038/s41591-021-01329-2
– volume: 131
  start-page: 865
  year: 2021
  ident: ref_3
  article-title: Prevalence of Olfactory Dysfunction in Coronavirus Disease 2019 (COVID-19): A Meta-analysis of 27,492 Patients
  publication-title: Laryngoscope
  doi: 10.1002/lary.29286
– volume: 395
  start-page: 1569
  year: 2020
  ident: ref_94
  article-title: Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)31022-9
– volume: 300
  start-page: 1763
  year: 2003
  ident: ref_36
  article-title: Coronavirus main proteinase (3CLpro) structure: Basis for design of anti-SARS drugs
  publication-title: Science
  doi: 10.1126/science.1085658
– volume: 395
  start-page: 507
  year: 2020
  ident: ref_25
  article-title: Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)30211-7
– volume: 585
  start-page: 588
  year: 2020
  ident: ref_24
  article-title: Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2
  publication-title: Nature
  doi: 10.1038/s41586-020-2575-3
– volume: 583
  start-page: 459
  year: 2020
  ident: ref_143
  article-title: A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
  publication-title: Nature
  doi: 10.1038/s41586-020-2286-9
– volume: 18
  start-page: 945
  year: 2021
  ident: ref_65
  article-title: SARS-CoV-2 nsp12 attenuates type I interferon production by inhibiting IRF3 nuclear translocation
  publication-title: Cell. Mol. Immunol.
  doi: 10.1038/s41423-020-00619-y
– volume: 93
  start-page: 6016
  year: 2021
  ident: ref_66
  article-title: Genomic characterization of SARS-CoV-2 isolates from patients in Turkey reveals the presence of novel mutations in spike and nsp12 proteins
  publication-title: J. Med. Virol.
  doi: 10.1002/jmv.27188
– volume: 12
  start-page: 23
  year: 2021
  ident: ref_141
  article-title: Large-Scale Multi-omic Analysis of COVID-19 Severity
  publication-title: Cell Syst.
  doi: 10.1016/j.cels.2020.10.003
– volume: 54
  start-page: 12
  year: 2021
  ident: ref_7
  article-title: A systematic review of asymptomatic infections with COVID-19
  publication-title: J. Microbiol. Immunol. Infect.
  doi: 10.1016/j.jmii.2020.05.001
– volume: 52
  start-page: 56
  year: 2020
  ident: ref_72
  article-title: Drug targets for corona virus: A systematic review
  publication-title: Indian J. Pharmacol.
  doi: 10.4103/ijp.IJP_115_20
– volume: 120
  start-page: 2793
  year: 2021
  ident: ref_117
  article-title: Small molecule therapeutics to destabilize the ACE2-RBD complex: A molecular dynamics study
  publication-title: Biophys. J.
  doi: 10.1016/j.bpj.2021.06.016
– volume: 16
  start-page: 1
  year: 2021
  ident: ref_62
  article-title: Efficacy and potential mechanisms of Chinese herbal compounds in coronavirus disease 2019: Advances of laboratory and clinical studies
  publication-title: Chin. Med.
  doi: 10.1186/s13020-021-00542-y
– volume: 12
  start-page: 5498
  year: 2021
  ident: ref_21
  article-title: CRISPR/Cas9 genetically engineered organoid biobank reveals essential host factors for coronaviruses
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-021-25729-7
– volume: 10
  start-page: e66815
  year: 2021
  ident: ref_23
  article-title: Human airway cells prevent SARS-CoV-2 multibasic cleavage site cell culture adaptation
  publication-title: Elife
  doi: 10.7554/eLife.66815
– volume: 60
  start-page: 6679
  year: 2016
  ident: ref_84
  article-title: Distinct effects of T-705 (favipiravir) and ribavirin on influenza virus replication and viral RNA synthesis
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.01156-16
– volume: 625
  start-page: 53
  year: 2022
  ident: ref_69
  article-title: ATP enhances the error-prone ribonucleotide incorporation by the SARS-CoV-2 RNA polymerase
  publication-title: Biochem. Biophys. Res. Commun.
  doi: 10.1016/j.bbrc.2022.07.087
– volume: 96
  start-page: e0067122
  year: 2022
  ident: ref_71
  article-title: The SARS-CoV nsp12 Polymerase Active Site Is Tuned for Large-Genome Replication
  publication-title: J. Virol.
  doi: 10.1128/jvi.00671-22
– volume: 4
  start-page: e213071
  year: 2021
  ident: ref_91
  article-title: Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19
  publication-title: JAMA Netw. Open
  doi: 10.1001/jamanetworkopen.2021.3071
– volume: 26
  start-page: 2100348
  year: 2021
  ident: ref_102
  article-title: Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: Data from seven EU/EEA countries, weeks 38/2020 to 10/2021
  publication-title: Euro Surveill
  doi: 10.2807/1560-7917.ES.2021.26.16.2100348
– volume: 112
  start-page: 101
  year: 2022
  ident: ref_48
  article-title: Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir
  publication-title: Clin. Pharmacol. Ther.
  doi: 10.1002/cpt.2603
– volume: 1257
  start-page: 132602
  year: 2022
  ident: ref_67
  article-title: Protein-protein interaction of RdRp with its co-factor NSP8 and NSP7 to decipher the interface hotspot residues for drug targeting: A comparison between SARS-CoV-2 and SARS-CoV
  publication-title: J. Mol. Struct.
  doi: 10.1016/j.molstruc.2022.132602
– volume: 894
  start-page: 173836
  year: 2021
  ident: ref_113
  article-title: Unraveling the mechanism of arbidol binding and inhibition of SARS-CoV-2: Insights from atomistic simulations
  publication-title: Eur. J. Pharmacol.
  doi: 10.1016/j.ejphar.2020.173836
– volume: 18
  start-page: 499
  year: 2021
  ident: ref_137
  article-title: Programmable RNA editing with compact CRISPR-Cas13 systems from uncultivated microbes
  publication-title: Nat. Methods
  doi: 10.1038/s41592-021-01124-4
– volume: 41
  start-page: 1100
  year: 2020
  ident: ref_20
  article-title: Mechanisms of SARS-CoV-2 Transmission and Pathogenesis
  publication-title: Trends Immunol.
  doi: 10.1016/j.it.2020.10.004
– volume: 73
  start-page: 736
  year: 2021
  ident: ref_120
  article-title: Ivermectin as a potential drug for treatment of COVID-19: An in-sync review with clinical and computational attributes
  publication-title: Pharmacol Rep.
  doi: 10.1007/s43440-020-00195-y
– volume: 183
  start-page: 1479
  year: 2020
  ident: ref_144
  article-title: Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19
  publication-title: Cell
  doi: 10.1016/j.cell.2020.10.037
– volume: 150
  start-page: 113058
  year: 2022
  ident: ref_79
  article-title: Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro
  publication-title: Biomed. Pharmacother.
  doi: 10.1016/j.biopha.2022.113058
– volume: 583
  start-page: 469
  year: 2020
  ident: ref_139
  article-title: Proteomics of SARS-CoV-2-infected host cells reveals therapy targets
  publication-title: Nature
  doi: 10.1038/s41586-020-2332-7
– volume: 65
  start-page: 618
  year: 2017
  ident: ref_133
  article-title: Cas13b Is a Type VI-B CRISPR-Associated RNA-Guided RNase Differentially Regulated by Accessory Proteins Csx27 and Csx28
  publication-title: Mol. Cell
  doi: 10.1016/j.molcel.2016.12.023
– volume: 374
  start-page: 1586
  year: 2021
  ident: ref_43
  article-title: An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19
  publication-title: Science
  doi: 10.1126/science.abl4784
– volume: 119
  start-page: e2117142119
  year: 2022
  ident: ref_33
  article-title: Structural basis for replicase polyprotein cleavage and substrate specificity of main protease from SARS-CoV-2
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.2117142119
– volume: 37
  start-page: 30
  year: 2022
  ident: ref_55
  article-title: Characterization of two SARS-CoV-2 subgenomic RNA dynamics in severe COVID-19 patients
  publication-title: Virol. Sin.
  doi: 10.1016/j.virs.2022.01.008
– volume: 105
  start-page: 107904
  year: 2021
  ident: ref_64
  article-title: Rutin and flavon.ne analogs as prospective SARS-CoV-2 main protease inhibitors: In silico drug discovery study
  publication-title: J. Mol. Graph. Model.
  doi: 10.1016/j.jmgm.2021.107904
– volume: 13
  start-page: 1
  year: 2022
  ident: ref_45
  article-title: The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-022-28354-0
– volume: 592
  start-page: 438
  year: 2021
  ident: ref_104
  article-title: Detection of a SARS-CoV-2 variant of concern in South Africa
  publication-title: Nature
  doi: 10.1038/s41586-021-03402-9
– volume: 50
  start-page: 576
  year: 2022
  ident: ref_47
  article-title: Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans
  publication-title: Drug Metab. Dispos.
  doi: 10.1124/dmd.121.000801
– volume: 23
  start-page: 100516
  year: 2021
  ident: ref_40
  article-title: In silico exploration of novel protease inhibitors against coronavirus 2019 (COVID-19)
  publication-title: Inform. Med. Unlocked
  doi: 10.1016/j.imu.2021.100516
– volume: 41
  start-page: 1167
  year: 2020
  ident: ref_61
  article-title: Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients
  publication-title: Acta Pharmacol. Sin.
  doi: 10.1038/s41401-020-0483-6
– ident: ref_86
– volume: 102
  start-page: 001558
  year: 2021
  ident: ref_34
  article-title: Targeting novel structural and functional features of coronavirus protease nsp5 (3CLpro, Mpro) in the age of COVID-19
  publication-title: J. Gen. Virol.
  doi: 10.1099/jgv.0.001558
– volume: 18
  start-page: 1
  year: 2021
  ident: ref_68
  article-title: Plant-Derived Natural Non-Nucleoside Analog Inhibitors (NNAIs) against RNA-Dependent RNA Polymerase Complex (nsp7/nsp8/nsp12) of SARS-CoV-2
  publication-title: J. Diet. Suppl.
– volume: 37
  start-page: 67
  year: 2017
  ident: ref_132
  article-title: Diversity, classification and evolution of CRISPR-Cas systems
  publication-title: Curr. Opin. Microbiol.
  doi: 10.1016/j.mib.2017.05.008
– volume: 12
  start-page: 671946
  year: 2021
  ident: ref_11
  article-title: Human beta cell regenerative drug therapy for diabetes: Past achievements and future challenges
  publication-title: Front. Endocrinol.
  doi: 10.3389/fendo.2021.671946
– volume: 593
  start-page: 136
  year: 2021
  ident: ref_109
  article-title: Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies
  publication-title: Nature
  doi: 10.1038/s41586-021-03412-7
– volume: 11
  start-page: 5047
  year: 2020
  ident: ref_50
  article-title: Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-18709-w
– volume: 19
  start-page: 4868
  year: 2021
  ident: ref_35
  article-title: An overview of potential inhibitors targeting non-structural proteins 3 (PLpro and Mac1) and 5 (3CLpro/Mpro) of SARS-CoV-2
  publication-title: Comput. Struct. Biotechnol. J.
  doi: 10.1016/j.csbj.2021.08.036
– volume: 19
  start-page: 171
  year: 2021
  ident: ref_6
  article-title: Considerations for diagnostic COVID-19 tests
  publication-title: Nat. Rev. Microbiol.
  doi: 10.1038/s41579-020-00461-z
– volume: 118
  start-page: e2025581118
  year: 2021
  ident: ref_124
  article-title: Network medicine framework for identifying drug-repurposing opportunities for COVID-19
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.2025581118
– volume: 10
  start-page: 587269
  year: 2020
  ident: ref_18
  article-title: SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development
  publication-title: Front. Cell Infect. Microbiol.
  doi: 10.3389/fcimb.2020.587269
– volume: 3
  start-page: 100072
  year: 2021
  ident: ref_53
  article-title: Predicting process design spaces for spray drying amorphous solid dispersions
  publication-title: Int. J. Pharm. X
– volume: 35
  start-page: 6417
  year: 2021
  ident: ref_148
  article-title: A triple-blind, placebo-controlled, randomized clinical trial to evaluate the effect of curcumin-containing nanomicelles on cellular immune responses subtypes and clinical outcome in COVID-19 patients
  publication-title: Phytother. Res.
  doi: 10.1002/ptr.7294
– volume: 185
  start-page: 104996
  year: 2021
  ident: ref_12
  article-title: Antiviral activity against Middle East Respiratory Syndrome coronavirus by Montelukast, an anti-asthma drug
  publication-title: Antivir. Res.
  doi: 10.1016/j.antiviral.2020.104996
– volume: 65
  start-page: e02428-20
  year: 2021
  ident: ref_77
  article-title: Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.02428-20
– volume: 113
  start-page: 1129
  year: 2021
  ident: ref_123
  article-title: Repurposed drugs and nutraceuticals targeting envelope protein: A possible therapeutic strategy against COVID-19
  publication-title: Genomics
  doi: 10.1016/j.ygeno.2020.11.009
– volume: 1224
  start-page: 129026
  year: 2021
  ident: ref_125
  article-title: Chemical-informatics approach to COVID-19 drug discovery: Exploration of important fragments and data mining based prediction of some hits from natural origins as main protease (Mpro) inhibitors
  publication-title: J. Mol. Struct.
  doi: 10.1016/j.molstruc.2020.129026
– volume: 19
  start-page: 4624
  year: 2020
  ident: ref_122
  article-title: Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning
  publication-title: J. Proteome Res.
  doi: 10.1021/acs.jproteome.0c00316
– volume: 146
  start-page: 110394
  year: 2021
  ident: ref_26
  article-title: Hypothesis: Alpha-1-antitrypsin is a promising treatment option for COVID-19
  publication-title: Med. Hypotheses
  doi: 10.1016/j.mehy.2020.110394
– volume: 297
  start-page: 100770
  year: 2021
  ident: ref_81
  article-title: Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template
  publication-title: J. Biol. Chem.
  doi: 10.1016/j.jbc.2021.100770
– volume: 59
  start-page: 100794
  year: 2021
  ident: ref_130
  article-title: An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment
  publication-title: Drug Resist. Updat.
  doi: 10.1016/j.drup.2021.100794
– volume: 11
  start-page: 23450
  year: 2021
  ident: ref_41
  article-title: Drug repurposing and computational modeling for discovery of inhibitors of the main protease (M pro) of SARS-CoV-2
  publication-title: RSC Adv.
  doi: 10.1039/D1RA03956C
– volume: 181
  start-page: 865
  year: 2020
  ident: ref_136
  article-title: Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza
  publication-title: Cell
  doi: 10.1016/j.cell.2020.04.020
– volume: 2
  start-page: e544
  year: 2021
  ident: ref_108
  article-title: Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): An observational study
  publication-title: Lancet Healthy Longev.
  doi: 10.1016/S2666-7568(21)00168-9
– volume: 381
  start-page: 215
  year: 2008
  ident: ref_97
  article-title: Importance of cholesterol-rich membrane microdomains in the interaction of the S protein of SARS-coronavirus with the cellular receptor angiotensin-converting enzyme 2
  publication-title: Virology
  doi: 10.1016/j.virol.2008.08.026
– volume: 5
  start-page: 27344
  year: 2020
  ident: ref_121
  article-title: Quantitative Structure-Activity Relationship Machine Learning Models and their Applications for Identifying Viral 3CLpro- and RdRp-Targeting Compounds as Potential Therapeutics for COVID-19 and Related Viral Infections
  publication-title: ACS Omega
  doi: 10.1021/acsomega.0c03682
– volume: 6
  start-page: 396
  year: 2021
  ident: ref_17
  article-title: The glycosylation in SARS-CoV-2 and its receptor ACE2
  publication-title: Signal. Transduct Target. Ther.
  doi: 10.1038/s41392-021-00809-8
– volume: 55
  start-page: 105948
  year: 2020
  ident: ref_1
  article-title: Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence
  publication-title: Int. J. Antimicrob. Agents
  doi: 10.1016/j.ijantimicag.2020.105948
– volume: 13
  start-page: 621
  year: 2022
  ident: ref_70
  article-title: A dual mechanism of action of AT-527 against SARS-CoV-2 polymerase
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-022-28113-1
– volume: 1
  start-page: 2000024
  year: 2021
  ident: ref_16
  article-title: Adsorption of SARS-CoV-2 Spike Protein S1 at Oxide Surfaces Studied by High-Speed Atomic Force Microscopy
  publication-title: Adv. Nanobiomed. Res.
  doi: 10.1002/anbr.202000024
– volume: 39
  start-page: e2000028
  year: 2020
  ident: ref_126
  article-title: Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds
  publication-title: Mol. Inform.
  doi: 10.1002/minf.202000028
– volume: 87
  start-page: 8017
  year: 2013
  ident: ref_116
  article-title: Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms
  publication-title: J. Virol.
  doi: 10.1128/JVI.00998-13
– volume: 73
  start-page: e4223
  year: 2020
  ident: ref_10
  article-title: Reinfection with SARS-CoV-2: Implications for Vaccines
  publication-title: Clin. Infect. Dis.
  doi: 10.1093/cid/ciaa1866
– volume: 63
  start-page: 12359
  year: 2020
  ident: ref_27
  article-title: COVID-19: Drug Targets and Potential Treatments
  publication-title: J. Med. Chem.
  doi: 10.1021/acs.jmedchem.0c00606
– volume: 379
  start-page: 1
  year: 2021
  ident: ref_112
  article-title: Insights into SARS-CoV-2: Medicinal chemistry approaches to combat its structural and functional biology
  publication-title: Top. Curr. Chem.
– volume: 579
  start-page: 270
  year: 2020
  ident: ref_110
  article-title: A pneumonia outbreak associated with a new coronavirus of probable bat origin
  publication-title: Nature
  doi: 10.1038/s41586-020-2012-7
– volume: 4
  start-page: 1011
  year: 2012
  ident: ref_95
  article-title: Mechanisms of coronavirus cell entry mediated by the viral spike protein
  publication-title: Viruses
  doi: 10.3390/v4061011
– volume: 8
  start-page: 1
  year: 2009
  ident: ref_142
  article-title: Extensions of sparse canonical correlation analysis with applications to genomic data
  publication-title: Stat. Appl. Genet. Mol. Biol.
  doi: 10.2202/1544-6115.1470
– volume: 10
  start-page: e64508
  year: 2021
  ident: ref_22
  article-title: SARS-CoV-2 entry into human airway organoids is serine protease-mediated and facilitated by the multibasic cleavage site
  publication-title: Elife
  doi: 10.7554/eLife.64508
– volume: 399
  start-page: 21
  year: 2022
  ident: ref_46
  article-title: Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management
  publication-title: Lancet
  doi: 10.1016/S0140-6736(21)02657-X
– volume: 11
  start-page: 222
  year: 2021
  ident: ref_146
  article-title: Identifying potential anti-COVID-19 pharmacological components of traditional Chinese medicine Lianhuaqingwen capsule based on human exposure and ACE2 biochromatography screening
  publication-title: Acta Pharm. Sin. B
  doi: 10.1016/j.apsb.2020.10.002
– volume: 30
  start-page: 269
  year: 2020
  ident: ref_89
  article-title: Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
  publication-title: Cell Res.
  doi: 10.1038/s41422-020-0282-0
– ident: ref_8
– volume: 383
  start-page: 2598
  year: 2020
  ident: ref_90
  article-title: FDA approval of remdesivir—A step in the right direction
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMp2032369
– volume: 133
  start-page: 104359
  year: 2021
  ident: ref_129
  article-title: Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning
  publication-title: Comput. Biol. Med.
  doi: 10.1016/j.compbiomed.2021.104359
– ident: ref_63
  doi: 10.3390/biomedicines9060689
– volume: 6
  start-page: 11
  year: 2021
  ident: ref_76
  article-title: Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets
  publication-title: Nat. Microbiol.
  doi: 10.1038/s41564-020-00835-2
– volume: 81
  start-page: 1548
  year: 2021
  ident: ref_93
  article-title: Remdesivir is a delayed translocation inhibitor of SARS-CoV-2 replication
  publication-title: Mol. Cell
  doi: 10.1016/j.molcel.2021.01.035
– volume: 19
  start-page: 149
  year: 2020
  ident: ref_30
  article-title: Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/d41573-020-00016-0
– volume: 101
  start-page: 107764
  year: 2022
  ident: ref_114
  article-title: Insights into binding molecular mechanism of hemagglutinin H3N2 of influenza virus complexed with arbidol and its derivative: A molecular dynamics simulation perspective
  publication-title: Comput. Biol. Chem.
  doi: 10.1016/j.compbiolchem.2022.107764
– volume: 7
  start-page: 226
  year: 2009
  ident: ref_96
  article-title: The spike protein of SARS-CoV—A target for vaccine and therapeutic development
  publication-title: Nat. Rev. Microbiol.
  doi: 10.1038/nrmicro2090
– volume: 36
  start-page: 1646
  year: 2021
  ident: ref_42
  article-title: Supervised Molecular Dynamics (SuMD) Insights into the mechanism of action of SARS-CoV-2 main protease inhibitor PF-07321332
  publication-title: J. Enzyme Inhib. Med. Chem.
  doi: 10.1080/14756366.2021.1954919
– volume: 22
  start-page: bbab211
  year: 2021
  ident: ref_127
  article-title: A transferable deep learning approach to fast screen potential antiviral drugs against SARS-CoV-2
  publication-title: Brief. Bioinform.
  doi: 10.1093/bib/bbab211
– ident: ref_44
  doi: 10.3390/ijms22179124
– volume: 87
  start-page: 3741
  year: 2013
  ident: ref_83
  article-title: T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro
  publication-title: J. Virol.
  doi: 10.1128/JVI.02346-12
– ident: ref_119
– volume: 37
  start-page: 109892
  year: 2021
  ident: ref_32
  article-title: Mechanistic insights into COVID-19 by global analysis of the SARS-CoV-2 3CL(pro) substrate degradome
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2021.109892
– ident: ref_115
  doi: 10.1186/s12879-020-05698-w
– volume: 23
  start-page: bbac226
  year: 2022
  ident: ref_39
  article-title: Generating and screening de novo compounds against given targets using ultrafast deep learning models as core components
  publication-title: Brief. Bioinform.
  doi: 10.1093/bib/bbac226
– volume: 145
  start-page: 105019
  year: 2021
  ident: ref_135
  article-title: CRISPR-cas13 enzymology rapidly detects SARS-CoV-2 fragments in a clinical setting
  publication-title: J. Clin. Virol.
  doi: 10.1016/j.jcv.2021.105019
– volume: 372
  start-page: eabg3055
  year: 2021
  ident: ref_100
  article-title: Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
  publication-title: Science
  doi: 10.1126/science.abg3055
– volume: 87
  start-page: 509
  year: 2018
  ident: ref_111
  article-title: Arbidol: A quarter-century after. Past, present and future of the original Russian antiviral
  publication-title: Russ. Chem. Rev.
  doi: 10.1070/RCR4791
– volume: 28
  start-page: e935952
  year: 2022
  ident: ref_73
  article-title: Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients
  publication-title: Med. Sci. Monit.
  doi: 10.12659/MSM.935952
– ident: ref_147
  doi: 10.3390/molecules26226900
– volume: 15
  start-page: 327
  year: 2016
  ident: ref_29
  article-title: Coronaviruses—Drug discovery and therapeutic options
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/nrd.2015.37
– volume: 2
  start-page: 100080
  year: 2021
  ident: ref_85
  article-title: Structural Basis of SARS-CoV-2 Polymerase Inhibition by Favipiravir
  publication-title: Innovation
– volume: 40
  start-page: 905
  year: 2021
  ident: ref_15
  article-title: COVID-19: Angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection
  publication-title: Eur. J. Clin. Microbiol. Infect. Dis.
  doi: 10.1007/s10096-020-04138-6
– volume: 397
  start-page: 2461
  year: 2021
  ident: ref_107
  article-title: SARS-CoV-2 Delta VOC in Scotland: Demographics, risk of hospital admission, and vaccine effectiveness
  publication-title: Lancet
  doi: 10.1016/S0140-6736(21)01358-1
– volume: 175
  start-page: 212
  year: 2018
  ident: ref_134
  article-title: Structural Basis for the RNA-Guided Ribonuclease Activity of CRISPR-Cas13d
  publication-title: Cell
  doi: 10.1016/j.cell.2018.09.001
– volume: 38
  start-page: 5464
  year: 2020
  ident: ref_2
  article-title: Discovery of novel serine/threonine protein phosphatase 1 inhibitors from traditional Chinese medicine through virtual screening and biological assays
  publication-title: J. Biomol. Struct. Dyn.
  doi: 10.1080/07391102.2019.1702588
– volume: 127
  start-page: 60
  year: 2019
  ident: ref_52
  article-title: Effect of plasticizers on manufacturing ritonavir/copovidone solid dispersions via hot-melt extrusion: Preformulation, physicochemical characterization, and pharmacokinetics in rats
  publication-title: Eur. J. Pharm. Sci.
  doi: 10.1016/j.ejps.2018.10.020
– volume: 133
  start-page: 9873
  year: 2021
  ident: ref_49
  article-title: Molecular Insights into Small-Molecule Drug Discovery for SARS-CoV-2
  publication-title: Angew. Chem.
  doi: 10.1002/ange.202008835
– volume: 11
  start-page: 4282
  year: 2020
  ident: ref_58
  article-title: Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-18096-2
– volume: 160
  start-page: e86
  year: 2021
  ident: ref_57
  article-title: Chronologic Bias, Confounding by Indication, and COVID-19 Care
  publication-title: Chest
  doi: 10.1016/j.chest.2021.01.087
– volume: 17
  start-page: 377
  year: 2022
  ident: ref_80
  article-title: Comprehensive review on molnupiravir in COVID-19: A novel promising antiviral to combat the pandemic
  publication-title: Future Microbiol.
  doi: 10.2217/fmb-2021-0252
– volume: 28
  start-page: 202
  year: 2021
  ident: ref_98
  article-title: A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent
  publication-title: Nat. Struct. Mol. Biol.
  doi: 10.1038/s41594-020-00549-3
– volume: 22
  start-page: 561
  year: 2021
  ident: ref_74
  article-title: Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2
  publication-title: Trials
  doi: 10.1186/s13063-021-05538-5
– volume: 184
  start-page: 3474
  year: 2021
  ident: ref_78
  article-title: Coupling of N7-methyltransferase and 3’-5’ exoribonuclease with SARS-CoV-2 polymerase reveals mechanisms for capping and proofreading
  publication-title: Cell
  doi: 10.1016/j.cell.2021.05.033
– volume: 368
  start-page: 1499
  year: 2020
  ident: ref_92
  article-title: Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir
  publication-title: Science
  doi: 10.1126/science.abc1560
– volume: 593
  start-page: 270
  year: 2021
  ident: ref_101
  article-title: Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7
  publication-title: Nature
  doi: 10.1038/s41586-021-03426-1
– ident: ref_51
  doi: 10.1201/9781003039235-23
– volume: 64
  start-page: 102634
  year: 2021
  ident: ref_59
  article-title: Nanotherapeutics for treating coronavirus diseases
  publication-title: J. Drug Deliv. Sci. Technol.
  doi: 10.1016/j.jddst.2021.102634
– volume: 101
  start-page: 106239
  year: 2021
  ident: ref_56
  article-title: Reporting and design of randomized controlled trials for COVID-19: A systematic review
  publication-title: Contemp. Clin. Trials
  doi: 10.1016/j.cct.2020.106239
– volume: 11
  start-page: 1
  year: 2021
  ident: ref_88
  article-title: SARS-CoV-2: From its discovery to genome structure, transcription, and replication
  publication-title: Cell Biosci.
  doi: 10.1186/s13578-021-00643-z
– volume: 18
  start-page: 1866
  year: 2021
  ident: ref_145
  article-title: A network pharmacology based approach for predicting active ingredients and potential mechanism of Lianhuaqingwen capsule in treating COVID-19
  publication-title: Int. J. Med. Sci.
  doi: 10.7150/ijms.53685
– volume: 94
  start-page: 1
  year: 2022
  ident: ref_118
  article-title: The outbreak of SARS-CoV-2 Omicron lineages, immune escape, and vaccine effectivity
  publication-title: J. Med. Virol.
– volume: 395
  start-page: 497
  year: 2020
  ident: ref_5
  article-title: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)30183-5
– volume: 18
  start-page: 784
  year: 2020
  ident: ref_128
  article-title: Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model
  publication-title: Comput. Struct. Biotechnol. J.
  doi: 10.1016/j.csbj.2020.03.025
– volume: 63
  start-page: 457
  year: 2020
  ident: ref_13
  article-title: Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission
  publication-title: Sci. China Life Sci.
  doi: 10.1007/s11427-020-1637-5
– ident: ref_60
  doi: 10.1051/e3sconf/202127302025
– volume: 9
  start-page: 221
  year: 2020
  ident: ref_14
  article-title: Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan
  publication-title: Emerg. Microbes. Infect.
  doi: 10.1080/22221751.2020.1719902
– volume: 119
  start-page: e2111199119
  year: 2022
  ident: ref_99
  article-title: SARS-CoV-2 spike engagement of ACE2 primes S2′ site cleavage and fusion initiation
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.2111199119
– volume: 12
  start-page: 1591
  year: 2022
  ident: ref_31
  article-title: Recent advances in developing small-molecule inhibitors against SARS-CoV-2
  publication-title: Acta Pharm. Sin. B
  doi: 10.1016/j.apsb.2021.06.016
– volume: 14
  start-page: 77
  year: 2020
  ident: ref_28
  article-title: A Review on Novel Drug Targets and Future Directions for COVID-19 Treatment
  publication-title: Biologics
– volume: 2
  start-page: e283
  year: 2021
  ident: ref_103
  article-title: SARS-CoV-2 spike E484K mutation reduces antibody neutralisation
  publication-title: Lancet Microbe
  doi: 10.1016/S2666-5247(21)00068-9
– volume: 12
  start-page: eabb5883
  year: 2020
  ident: ref_75
  article-title: An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice
  publication-title: Sci. Transl. Med.
  doi: 10.1126/scitranslmed.abb5883
– volume: 150
  start-page: 104641
  year: 2021
  ident: ref_38
  article-title: Structural and functional insights into non-structural proteins of coronaviruses
  publication-title: Microb. Pathog.
  doi: 10.1016/j.micpath.2020.104641
SSID ssj0021415
Score 2.4014924
SecondaryResourceType review_article
Snippet COVID-19 is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel highly contagious and pathogenic coronavirus...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 8257
SubjectTerms Antiviral agents
Antiviral Agents - chemistry
Antiviral Agents - pharmacology
Antiviral Agents - therapeutic use
Antiviral drugs
Bioavailability
Biosynthesis
Chemotherapy
China
Clinical trials
Coronaviruses
COVID-19
COVID-19 vaccines
CRISPR/Cas
Cytokine storm
deep learning
Disease prevention
Disease transmission
Drug development
drug target
Drug therapy
Enzymes
Epidemics
Experiments
Genomes
Humans
Interferon
multiomics analysis
Pandemics
Proteins
Review
SARS-CoV-2
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Technology
Vaccines
Viral infections
Viruses
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8QwEA6yF72Ib-uLCIIgFJu0TTZHXVdWD6sHlb2FJk1RWLvirgf_vTN92SLoxVtpJpBMJjPftPMg5CQNAKQCTvYTFlk_Mir1je3Ddc9imRnFXWKKANmxGD1Gt5N40mr1hTFhZXngknHn1rI04YpbKUDYTGxsaLGGXgB2PVSmqAQKNq92pipXi4FdKv9hhuDUn7-WrWbdnGOPLY62qGWFimL9P1VyyyZ14yVbBuh6jaxWyJFelCteJ0su3yDLg7ph2yYZ3mOsFWguOsvp4O7p5spniiJBO8tqTq9e5hYDNz9pkqd0DI9T-v2FfYs8Xg8fBiO_6pLgW0ArCx80VgGzHDAqNhHLMkAAIsikLLCSMg7djNg6GRsllAktYKSUc5ZJngrTD7dJL5_lbpfQhIFrDTrAOhVEzliYa2JnIsUzLkAbeSSouaZtVUIcO1lMNbgSyGj9g9EeOWumvJX1M34jvsSjaAix9HXxAgRCVwKh_xIIj5ziQWq8oLA4m1R5BrBFLHWlL2QUY_qtEh456FDCcdnucC0KurrYcw1OfB-dWAnDx80wzsRgtdzNPpAGMDQmpTOP7JSS02wphKMKwgi2Kjsy1dlzdyR_eS7KfisZCsCPe__BpH2ywjGPgzGfiwPSW7x_uENAVwtzVFykLzC0Ick
  priority: 102
  providerName: Directory of Open Access Journals
Title Progress on COVID-19 Chemotherapeutics Discovery and Novel Technology
URI https://www.ncbi.nlm.nih.gov/pubmed/36500347
https://www.proquest.com/docview/2748560176
https://www.proquest.com/docview/2753318521
https://pubmed.ncbi.nlm.nih.gov/PMC9736643
https://doaj.org/article/cc1da292c76048b5bc3c4379092939b4
Volume 27
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB5Be4ALgvJooKyMhISEFDV2HHt9Qu12t4XDUiGK9mbFjgOV2qQ02wP_npkk-4gq9bKK1mMp4xmPv3HmAfCxSBCkIk6Ocy59LJ0pYufHuN3LTJfOiJC7NkB2rs4u5LdFtugv3Jo-rHJlE1tDXdSe7sgP0Xsak_eg1ZebvzF1jaKvq30LjcewS6XLSKv1YuNwcTydui-ZKbr2h9ddw9nQCOq0JehE2jqL2pL99w3z1sk0jJrcOoZmz-FZjx_ZUSfwF_AoVHvwZLJq2_YSpucUcYX2i9UVm3z_9fUk5oYRwXauVcNOLhtP4Zv_WF4VbI6PV2xzz_4KLmbTn5OzuO-VEHtclWWMdqsFW8HzInOSlyXiAJWUWreIybhAzkbmg86cUcalHpFSIQQvtSiUG6evYaeqq7APLOfoYKMl8MEkMjiPc10WnDSiFAptUgTJatWs7wuJUz-LK4sOBS20vbfQEXxeT7npqmg8RHxMolgTUgHs9o_69rft95P1yGcujPBaoQ1ymfOpp9KKCcI95FZG8IkEaWmb4sv5vM82QBap4JU90jKjJFyjIjgYUKK4_HB4pQq2396N3ShjBB_WwzSTQtaqUN8RDSJpSk3nEbzpNGfNUoqiSlKJrOqBTg14Ho5Ul3_a4t9GpwpR5NuHX-sdPBWUp8F5LNQB7Cxv78J7RE9LN2q3CP6OZ6cj2D2ezs9_jNqbiP_7aB1u
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VcigXxJtAASOBkJCiJo5jrw8Ild0uu7QsHFrUWxo7DlQqSWm2Qv1T_EZm8upGlXrrLYrHUcYez3yTzAPgTRYgSEWc7KehsL4wOvONHeFxz2OVG81dauoA2YWcHYgvh_HhGvzrcmEorLLTibWizkpL38i30Hsakfeg5MfTPz51jaK_q10LjUYsdt3FX3TZqg_zCe7vW86nO_vjmd92FfAtzl_6eMJrWOJsmMVGhHmOFlMGuVI1ttDGESyPrVOx0VKbyCKmyDgPc8UzaUYRPvcW3BYRWnLKTJ9-7h28EK1h8-cUB4Ot302DW1dx6uzFyQKu2L66RcBVQ7BiCYdRmitmb3oP7rZ4lW03AnYf1lzxADbGXZu4h7DznSK8UF-ysmDjbz_mEz_UjAhWc7sqNjmuLIWLXrC0yNgCL0_Y5Xf9R3BwI6v4GNaLsnBPgaUhOvSoeazTgXDG4lwTOyM0z7lEHehB0K1aYtvC5dQ_4yRBB4YWOrmy0B6876ecNlU7riP-RFvRE1LB7fpGefYzac9vYpHPlGtulUSdZ2JjI0ulHAOEl8it8OAdbWRCagFfzqZtdgOySAW2km0lYkr61dKDzQElbpcdDneikLTqpEouhd-D1_0wzaQQucKV50SDyJ1S4UMPnjSS07MU4VYFkUBW1UCmBjwPR4rjX3Wxca0iiaj12fWv9Qo2Zvtf95K9-WL3OdzhlCMShj6Xm7C-PDt3LxC5Lc3L-rgwOLrp8_kfgWpUVQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3da9RAEB_qFdQX8dto1RUUQQiXbJLd2weR9j7oWTkPsdK3NLvZ2EKb1OaK9F_zr3MmX71Q6FvfQnY2ZHZ3Zn6TzAfA-9RDkIo42U380LihVqmrzQjFPYtkphW3ia4CZBdidz_8ehAdbMC_NheGwipbnVgp6rQw9I18iN7TiLwHKYZZExaxnMy-nP1xqYMU_Wlt22nUR2TPXv5F9638PJ_gXn_gfDb9Od51mw4DrsFnrVyU9gqiWOOnkQ79LEPrKbxMygpnKG0JokfGykgroXRgEF-knPuZ5KnQowCfewc2JXlFA9jcmS6WPzp3z0fbWP9HDQLlDU_rdre25NTni5M9XLOEVcOA62ZhzS72YzbXjODsITxo0Cvbro_bI9iw-WO4N26bxj2B6ZLivVB7siJn4--_5hPXV4wI1jO9SjY5Lg0Fj16yJE_ZAi9P2NVX_qewfyvr-AwGeZHbF8ASH9171EPGKi-02uBcHVkdKp5xgRrRAa9dtdg0Zcypm8ZJjO4MLXR8baEd-NRNOatreNxEvENb0RFS-e3qRnH-O26kOTbIZ8IVN1KgBtSRNoGhwo4egk3kNnTgI21kTEoCX84kTa4DskjltuJtGUaUAqyEA1s9Stwu0x9uj0LcKJcyvhIFB951wzSTAuZyW1wQDeJ4Soz3HXhen5yOpQC3ygtCZFX2zlSP5_5IfnxUlR5XMhCIYV_e_Fpv4S7KZvxtvth7Bfc5JYz4vsvFFgxW5xf2NcK4lX7TyAuDw9sW0f8f2Vnn
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Progress+on+COVID-19+Chemotherapeutics+Discovery+and+Novel+Technology&rft.jtitle=Molecules+%28Basel%2C+Switzerland%29&rft.au=Zhou%2C+Yalan&rft.au=Wang%2C+Huizhen&rft.au=Yang%2C+Li&rft.au=Wang%2C+Qingzhong&rft.date=2022-11-26&rft.issn=1420-3049&rft.eissn=1420-3049&rft.volume=27&rft.issue=23&rft_id=info:doi/10.3390%2Fmolecules27238257&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1420-3049&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1420-3049&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1420-3049&client=summon